Neurocentria, Inc.   Report issue

For profit Phase 3 Phase 4
Founded: Walnut Creek CA United States (2005)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2014
NCT02237235
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Neurocentria, Inc.